🇺🇸 FDA
Patent

US 9456997

Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure

granted A61KA61K31/137A61K31/138

Quick answer

US patent 9456997 (Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/137, A61K31/138, A61K31/165, A61K31/35